Browsing Tag
Pfizer
121 posts
Valneva slashes 2025 outlook after FDA suspends Ixchiq license, shaking investor confidence
Valneva slashes 2025 outlook after FDA suspends Ixchiq license—discover how the biotech aims to rebuild confidence and cash flow stability.
Enanta Pharmaceuticals to reveal Phase 2b RSV trial results—can zelicapavir change treatment for high-risk adults?
Enanta Pharmaceuticals will present Phase 2b zelicapavir results in RSV high-risk adults. See why this trial matters for investors, patients, and the RSV market.
AstraZeneca just joined the direct-to-consumer drug race — here’s what it means for patients and rivals
AstraZeneca launches AstraZeneca Direct in the U.S. with up to 70% discounts. Explore how this direct-to-consumer model could reshape drug access.
Pfizer to buy Metsera in $7.3bn obesity drug deal, challenging Lilly and Novo
Pfizer’s $7.3B Metsera takeover could reshape the GLP-1 obesity drug race and challenge Eli Lilly and Novo Nordisk’s dominance in weight loss treatments.
Formation Bio hires ex-Pfizer and BenevolentAI leaders to supercharge its AI-driven drug development model
Formation Bio bolsters its leadership team with top biotech and pharma veterans to fast-track its AI-driven drug development model.
FDA acceptance of Sarfaraz Niazi’s biosimilar petition could reset the economics of monoclonal antibody approvals
FDA accepts Sarfaraz Niazi’s petition to waive costly clinical efficacy studies for monoclonal antibody biosimilars, reshaping drug affordability worldwide.
Daiichi Sankyo launches development of oral triple combination tablets for LDL cholesterol management in Europe
Daiichi Sankyo (TYO: 4568) begins developing oral triple therapy with bempedoic acid, ezetimibe, and statins to transform LDL cholesterol management in Europe.
Can seasonal COVID‑19 shots follow the flu vaccine playbook—and will Americans comply in 2025?
Will Americans embrace annual COVID-19 shots like flu vaccines? Explore how LP.8.1, FDA guidance, and public trust shape the 2025 rollout.
Pfizer and BioNTech secure FDA approval for LP.8.1-adapted COMIRNATY vaccine for high-risk groups
Pfizer and BioNTech's LP.8.1-adapted COVID-19 vaccine gets FDA approval for high-risk groups. Find out what this means for the 2025–2026 rollout season.
XtalPi and Pfizer deepen AI-powered drug discovery alliance with enhanced molecular modeling platform for small molecule breakthroughs
XtalPi expands collaboration with Pfizer to build high-throughput AI-driven molecular modeling platform for small molecule discovery. Read the full strategic update.